Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review.

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2025-01-14 DOI:10.1111/dom.16189

Ming Xu, Dongqing Lv, Hongxia Wei, Zhe Li, Shuqing Jin, Qinhao Liu, Yi Zhang, Yunfeng Liu

{"title":"Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review.","authors":"Ming Xu, Dongqing Lv, Hongxia Wei, Zhe Li, Shuqing Jin, Qinhao Liu, Yi Zhang, Yunfeng Liu","doi":"10.1111/dom.16189","DOIUrl":null,"url":null,"abstract":"<p><p>Metabolic syndrome-related diseases frequently involve disturbances in skeletal muscle lipid metabolism. The accumulation of lipid metabolites, lipid-induced mitochondrial stress in skeletal muscle cells, as well as the inflammation of adjacent adipose tissue, are associated with the development of insulin resistance and metabolic dysfunction. Consequently, when antidiabetic medications are used to treat various chronic conditions related to hyperglycaemia, the impact on skeletal muscle lipid metabolism should not be overlooked. However, current research has predominantly focused on muscle mass rather than skeletal muscle lipid metabolism and its interplay with glucose metabolism. In this review, we summarised the latest research on the effects of antidiabetic drugs and certain natural compounds with antidiabetic activity on skeletal muscle lipid metabolism, focusing on data from preclinical to clinical studies. Given the widespread use of antidiabetic drugs, a better understanding of their effects on skeletal muscle lipid metabolism merits further attention in future research.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16189","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Metabolic syndrome-related diseases frequently involve disturbances in skeletal muscle lipid metabolism. The accumulation of lipid metabolites, lipid-induced mitochondrial stress in skeletal muscle cells, as well as the inflammation of adjacent adipose tissue, are associated with the development of insulin resistance and metabolic dysfunction. Consequently, when antidiabetic medications are used to treat various chronic conditions related to hyperglycaemia, the impact on skeletal muscle lipid metabolism should not be overlooked. However, current research has predominantly focused on muscle mass rather than skeletal muscle lipid metabolism and its interplay with glucose metabolism. In this review, we summarised the latest research on the effects of antidiabetic drugs and certain natural compounds with antidiabetic activity on skeletal muscle lipid metabolism, focusing on data from preclinical to clinical studies. Given the widespread use of antidiabetic drugs, a better understanding of their effects on skeletal muscle lipid metabolism merits further attention in future research.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

降糖药对骨骼肌脂质代谢的影响：综述。

代谢综合征相关疾病常涉及骨骼肌脂质代谢紊乱。脂质代谢物的积累、骨骼肌细胞中脂质诱导的线粒体应激以及邻近脂肪组织的炎症与胰岛素抵抗和代谢功能障碍的发生有关。因此，当降糖药物用于治疗与高血糖相关的各种慢性疾病时，对骨骼肌脂质代谢的影响不容忽视。然而，目前的研究主要集中在肌肉质量上，而不是骨骼肌脂质代谢及其与葡萄糖代谢的相互作用。本文综述了近年来有关抗糖尿病药物和某些具有抗糖尿病活性的天然化合物对骨骼肌脂质代谢影响的最新研究进展，重点介绍了临床前和临床研究的数据。鉴于抗糖尿病药物的广泛应用，更好地了解其对骨骼肌脂质代谢的影响值得在未来的研究中进一步关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.